Related Experiment Videos
CD44 splice variants: expression during lymphocyte activation and tumor progression
S T Pals1, G Koopman, K H Heider
1Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands.
Behring Institute Mitteilungen
|August 1, 1993
Summary
Variant CD44 glycoproteins, particularly exon v6, are linked to metastasis in cancers. Overexpression is observed in aggressive non-Hodgkin
Area of Science:
- Molecular Biology
- Oncology
- Immunology
Background:
- A CD44 splice variant confers metastatic potential in rat models.
- Understanding variant CD44 expression is crucial for cancer research.
Purpose of the Study:
- To investigate the expression of variant CD44 glycoproteins in human lymphoid cells, non-Hodgkin's lymphomas (NHL), and colorectal neoplasia.
- To determine if variant CD44, specifically exon v6, correlates with cancer aggressiveness and metastasis.
Main Methods:
- Utilized antibodies against bacterial fusion proteins encoded by variant CD44 sequences.
- Examined expression patterns in normal human lymphohematopoietic cells, activated T lymphocytes, NHL tissues, and colorectal neoplasia (polyps and carcinomas).
Main Results:
- Normal lymphohematopoietic cells show minimal variant CD44 expression; activated T cells upregulate it transiently.
- Variant CD44 glycoproteins containing the exon v6 domain are overexpressed in aggressive NHL but not low-grade types.
- Strong overexpression of CD44 splice variants, including focal expression in dysplastic areas of polyps, is evident in invasive colorectal carcinomas and metastases.
Conclusions:
- CD44 splice variants, particularly those with exon v6, are associated with cancer progression and metastasis.
- Variant CD44 serves as a potential tumor progression marker in colorectal cancer.
- Exon v6-containing CD44 variants may play a role in the metastatic capability of human cancers.